MX383462B - Pridopidina para el tratamiento de las discinesias inducidas por fármacos - Google Patents
Pridopidina para el tratamiento de las discinesias inducidas por fármacosInfo
- Publication number
- MX383462B MX383462B MX2020002645A MX2020002645A MX383462B MX 383462 B MX383462 B MX 383462B MX 2020002645 A MX2020002645 A MX 2020002645A MX 2020002645 A MX2020002645 A MX 2020002645A MX 383462 B MX383462 B MX 383462B
- Authority
- MX
- Mexico
- Prior art keywords
- drug
- subject
- pridopidine
- induced
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556314P | 2017-09-08 | 2017-09-08 | |
| US201862649184P | 2018-03-28 | 2018-03-28 | |
| PCT/US2018/048920 WO2019050775A1 (en) | 2017-09-08 | 2018-08-30 | PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020002645A MX2020002645A (es) | 2021-06-10 |
| MX383462B true MX383462B (es) | 2025-03-14 |
Family
ID=63684481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002645A MX383462B (es) | 2017-09-08 | 2018-08-30 | Pridopidina para el tratamiento de las discinesias inducidas por fármacos |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190231768A1 (OSRAM) |
| EP (1) | EP3678664A1 (OSRAM) |
| JP (1) | JP2020533296A (OSRAM) |
| CN (1) | CN111343982A (OSRAM) |
| AU (1) | AU2018329628B2 (OSRAM) |
| BR (1) | BR112020004622A2 (OSRAM) |
| CA (1) | CA3075020C (OSRAM) |
| IL (1) | IL273044A (OSRAM) |
| MX (1) | MX383462B (OSRAM) |
| WO (1) | WO2019050775A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| KR20250021199A (ko) | 2023-08-03 | 2025-02-12 | 재단법인대구경북과학기술원 | 파킨슨 환자의 lid 발병 예측을 위한 정보제공방법 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| JP5393654B2 (ja) | 2007-04-12 | 2014-01-22 | イヴァックス インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツンク | 改善された心血管副作用プロフィールを呈する、ドーパミン受容体安定剤／調節剤のｎ−オキシド誘導体及び／又はジ−ｎ−オキシド誘導体 |
| US20100197712A1 (en) | 2007-06-18 | 2010-08-05 | Arvid Carlsson | Use of dopamine stabilizers |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| CN103080343A (zh) | 2010-07-02 | 2013-05-01 | Skf公司 | 机械部件和用于表面硬化的方法 |
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
| US20130267552A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
| WO2014205229A1 (en) | 2013-06-21 | 2014-12-24 | IVAX International GmbH | Use of high dose pridopidine for treating huntington's disease |
| DK177976B8 (en) | 2013-07-10 | 2021-04-22 | Jasopels As | Apparatus and method for stretching a pelt on a pelt board |
| MX377576B (es) | 2014-01-22 | 2025-03-04 | Prilenia Neurotherapeutics Ltd | Formulaciones de pridopidina de liberación modificada. |
| WO2015138130A1 (en) | 2014-03-10 | 2015-09-17 | Applied Materials, Inc. | Pixel blending for multiple charged-particle beam lithography |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| US9796673B2 (en) | 2014-12-22 | 2017-10-24 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| WO2016138130A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine to improve cognitive function and for treating alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017015615A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| CA3015512C (en) | 2016-02-24 | 2024-01-16 | Teva Pharmaceuticals International Gmbh | Treatment of neurodegenerative eye disease using pridopidine |
| CA3035092C (en) | 2016-08-24 | 2022-05-31 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating functional decline |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| WO2018053287A1 (en) | 2016-09-15 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of anxiety and depression |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| AU2018210145B2 (en) | 2017-01-20 | 2023-06-29 | Agency For Science, Technology And Research | Use of pridopidine for the treatment of fragile X syndrome |
| BR112020003119A2 (pt) | 2017-08-14 | 2020-10-13 | Prilenia Neurotherapeutics Ltd. | método de tratamento de esclerose lateral amiotrófica com pridopidina |
| EP3675830A1 (en) * | 2017-08-30 | 2020-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| DE102018204527A1 (de) | 2017-09-18 | 2019-03-21 | SEs Solutions GmbH | Dachhalterung für ein Automobil |
-
2018
- 2018-08-30 EP EP18778648.8A patent/EP3678664A1/en active Pending
- 2018-08-30 MX MX2020002645A patent/MX383462B/es unknown
- 2018-08-30 CN CN201880072818.0A patent/CN111343982A/zh active Pending
- 2018-08-30 BR BR112020004622-1A patent/BR112020004622A2/pt not_active IP Right Cessation
- 2018-08-30 AU AU2018329628A patent/AU2018329628B2/en active Active
- 2018-08-30 CA CA3075020A patent/CA3075020C/en active Active
- 2018-08-30 WO PCT/US2018/048920 patent/WO2019050775A1/en not_active Ceased
- 2018-08-30 JP JP2020513603A patent/JP2020533296A/ja active Pending
-
2019
- 2019-04-08 US US16/377,577 patent/US20190231768A1/en not_active Abandoned
- 2019-06-11 US US16/436,947 patent/US11000519B2/en active Active
-
2020
- 2020-03-03 IL IL273044A patent/IL273044A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020002645A (es) | 2021-06-10 |
| US20190231768A1 (en) | 2019-08-01 |
| US11000519B2 (en) | 2021-05-11 |
| CA3075020A1 (en) | 2019-03-14 |
| IL273044A (en) | 2020-04-30 |
| US20190350914A1 (en) | 2019-11-21 |
| WO2019050775A1 (en) | 2019-03-14 |
| EP3678664A1 (en) | 2020-07-15 |
| CA3075020C (en) | 2021-12-07 |
| CN111343982A (zh) | 2020-06-26 |
| BR112020004622A2 (pt) | 2020-09-24 |
| AU2018329628B2 (en) | 2021-04-22 |
| AU2018329628A1 (en) | 2020-04-16 |
| JP2020533296A (ja) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX383462B (es) | Pridopidina para el tratamiento de las discinesias inducidas por fármacos | |
| BR112019003731A2 (pt) | aplicação de pridopidina para tratamento de distonias | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| CL2020002019A1 (es) | Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582) | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| MX2023000251A (es) | Composiciones para usarse en el tratamiento de un trastorno asociado a gen de proproteina convertasa subtilisina kexina (pcsk9). | |
| MX2015009963A (es) | Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía. | |
| MX377141B (es) | Composiciones y metodos para modular la expresion de pkk. | |
| AR086582A1 (es) | Anticuerpos anti-kir para el tratamiento de trastornos inflamatorios y autoinmunes | |
| MX389437B (es) | Composiciones para modular la expresion de ataxina 2. | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| MX2019007161A (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| CO2019011265A2 (es) | Moduladores de la expresión de pcsk9 | |
| AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
| EA036102B9 (ru) | Терапевтические средства с углевод-опосредованной адресной доставкой | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| BR112015019564A2 (pt) | tratamento de esclerose múltipla com laquinimod | |
| BR112014030279A2 (pt) | métodos para tratamento de neutropenia usando agonistas retinóide | |
| EA201992248A1 (ru) | АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ | |
| EA201792641A1 (ru) | Ингибитор оси igfbp3/tmem219 и диабет | |
| UY38506A (es) | Composiciones y metodos para tratar y prevenir la esclerosis lateral amiotrofica | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| BR112019000635A2 (pt) | inibidor de receptor 2 do tipo toll (tlr2) e seu uso, anticorpo, composição e método para tratar uma afecção inflamatória | |
| MX2022013283A (es) | Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales. | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 |